Pharma BD Deal Intelligence
GSK and Pfizer combined their consumer healthcare businesses into a joint venture with GSK holding 68% and Pfizer 32%. The JV combined brands including Advil, Centrum, Sensodyne, and Voltaren. GSK did not pay cash but contributed its consumer healthcare business. The JV was later spun off as Haleon in July 2022. Combined revenue ~$12.7B at formation. Post-demerger, both founding parents fully exited their residual stakes: GSK in May 2024 and Pfizer in March 2025 (7.3% to nil, ~GBP2.55B/$3.3B), completing the separation.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Pfizer Inc. (this deal) | 2018 | $0.0M | 77 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
| GSK plc / Human Genome Sciences | 2012 | $3.6B | 70 |
← Browse all deals · How we score deals
More: 2018 deals · GSK plc deals